Palvella Therapeutics, Inc. (PVLA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $115.50: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum.
Palvella Therapeutics is a clinical-stage biopharma using its QTORIN platform to develop topical therapies for rare skin diseases and vascular malformations. Lead asset QTORIN rapamycin met its primary endpoint in the Phase 3 SELVA trial for microcystic lymphatic malformations... Read more
Sell if holding. Engine safety override at $115.50: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Palvella Therapeutics, Inc.
Latest news
- Palvella Therapeutics Presents New Clinical Data From Phase 3 SELVA And Phase 2 TOIVA Studies At ISSVA World Congress 20 — benzinga May 20, 2026 positive
- Palvella Therapeutics Presents New Data From Phase 2 TOIVA Trial Of QTORIN Rapamycin In Patients With Cutaneous Venous M — benzinga May 15, 2026 positive
- Palvella Therapeutics Receives Approval To Uplist To Nasdaq Global Market — benzinga May 13, 2026 positive
- Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220 — benzinga May 12, 2026 positive
- Palvella Therapeutics Q1 EPS $(1.20) Misses $(0.93) Estimate — benzinga May 7, 2026 negative
Generated 2026-05-20T21:56:22Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineQTORIN rapamycin10-K Item 1A: 'Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of QTORIN rapamycin, which is in later stages of development than our other product candidates.'
Material Events(8-K, last 90d)
- 2026-04-13Item 5.02LOWBoard increased from 6 to 7 members; John Doux, M.D. appointed as Class III director effective April 13, 2026 (term expiring at 2026 Annual Meeting). Routine board expansion; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 7.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $115.50: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $107.42. Score 4.9/10, moderate confidence.
Take-profit target: $206.10 (+78.4% upside). Prior stop was $107.42. Stop-loss: $107.42.
Concentration risk — Pipeline: QTORIN rapamycin; Quality below floor (1.2 < 4.0).
Palvella Therapeutics, Inc. trades at a P/E of N/A (forward -16.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover PVLA with a consensus score of 4.2/5. Average price target: $229.
What does Palvella Therapeutics, Inc. do?Palvella Therapeutics is a clinical-stage biopharma using its QTORIN platform to develop topical therapies for rare...
Palvella Therapeutics is a clinical-stage biopharma using its QTORIN platform to develop topical therapies for rare skin diseases and vascular malformations. Lead asset QTORIN rapamycin met its primary endpoint in the Phase 3 SELVA trial for microcystic lymphatic malformations (February 2026); NDA submission is planned for H2 2026. QTORIN pitavastatin targets DSAP in IND-enabling development.